NCT01189370View on ClinicalTrials.gov

Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Renal Cell Cancer

Interventions

DRUG

sorafenib

"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

University of Kansas Medical Center

OTHER